23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Arcus Biosciences, Inc. › 2025-2026

Arcus Biosciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 250Asset managers, any item
  • 1,990Fund votes
  • June 11, 2026Meeting date

Results at a glance

Meeting of June 11, 2026: 6 items on Arcus Biosciences, Inc.’s Form 8-K, filed June 12, 2026: 6 passed (calculated).

Dissent

Notable dissent: 4 directors (17.6%, 17.6%, 17.6%, 11.2% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Arcus Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Arcus Biosciences, Inc.

These tallies are Arcus Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Arcus Biosciences, Inc. — official shareholder meeting results, meeting held June 11, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dietmar Berger, M.D., Ph.D. 85,949,508---- 18,338,02213,573,227 82%Passed (calculated)—
Elect Director: David Lacey, M.D. 85,974,583---- 18,312,94713,573,227 82%Passed (calculated)—
Elect Director: Nicole Lambert 92,653,341---- 11,634,18913,573,227 89%Passed (calculated)—
Elect Director: Johanna Mercier 85,941,754---- 18,345,77613,573,227 82%Passed (calculated)—
2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 112,905,5824,767,430187,745 ---- 96%Passed (calculated)—
3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement 94,920,4219,337,36829,741 --13,573,227 91%Passed (calculated)—

Source: Arcus Biosciences, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Arcus Biosciences, Inc. 2025-2026 meeting

250 asset managers disclosed a vote on at least one Arcus Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: David Lacey, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 85,974,583WITHHELD: 18,312,947
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: David Lacey, M.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: David Lacey, M.D.”): 85,974,583 for, 18,312,947 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 27,294,920 for, 6,096,290 withheld, 132 abstained.

FORWITHHOLD
FOR: 27,294,920ABSTAIN: 132WITHHOLD: 6,096,290
Largest asset managers voting on “Election of Directors: David Lacey, M.D.” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,445,2140 1320For
BlackRock10,028,5410 00For
State Street8,2450 03,649,002Withhold
Fidelity3,158,4970 00For
Charles Schwab768,3500 00For
Delaware/Macquarie00 0379,100Withhold
Aberdeen00 0266,041Withhold
First Trust00 0241,689Withhold
TIAA00 0210,638Withhold
Hartford182,8090 00For
Equitable119,4560 058,100Mixed
Jackson National00 0149,532Withhold
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle00 0129,106Withhold
Invesco00 0100,687Withhold
Tema ETF Trust84,2140 00For
Prudential/PGIM66,7230 011,406Mixed
Thrivent00 077,528Withhold
BNY Mellon00 074,700Withhold
Bridge Builder Trust22,0580 051,408Mixed
Principal00 072,189Withhold
ProShares00 066,038Withhold
Empower00 060,027Withhold
Lincoln Financial00 058,201Withhold
Northern Trust00 049,426Withhold

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Dietmar Berger, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 85,949,508WITHHELD: 18,338,022
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Dietmar Berger, M.D., Ph.D.

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Dietmar Berger, M.D., Ph.D.”): 85,949,508 for, 18,338,022 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,355,930 for, 3,035,272 withheld, 140 abstained.

FOR
FOR: 30,355,930ABSTAIN: 140WITHHOLD: 3,035,272
Largest asset managers voting on “Election of Directors: Dietmar Berger, M.D., Ph.D.” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,410,2560 14034,950For
BlackRock10,028,5410 00For
State Street3,646,5320 010,715For
Fidelity3,158,4970 00For
Charles Schwab00 0768,350Withhold
Delaware/Macquarie00 0379,100Withhold
Aberdeen00 0266,041Withhold
First Trust00 0241,689Withhold
TIAA00 0210,638Withhold
Hartford182,8090 00For
Equitable119,4560 058,100Mixed
Jackson National130,9630 018,569Mixed
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle00 0129,106Withhold
Invesco100,6870 00For
Tema ETF Trust00 084,214Withhold
Prudential/PGIM00 078,129Withhold
Thrivent00 077,528Withhold
BNY Mellon74,7000 00For
Bridge Builder Trust22,0580 051,408Mixed
Principal00 072,189Withhold
ProShares00 066,038Withhold
Empower00 060,027Withhold
Lincoln Financial51,1000 07,101Mixed
Northern Trust49,4260 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Johanna Mercier

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%WITHHELD
FOR: 85,941,754WITHHELD: 18,345,776
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Johanna Mercier

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Johanna Mercier”): 85,941,754 for, 18,345,776 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,355,930 for, 3,035,272 withheld, 140 abstained.

FOR
FOR: 30,355,930ABSTAIN: 140WITHHOLD: 3,035,272
Largest asset managers voting on “Election of Directors: Johanna Mercier” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,410,2560 14034,950For
BlackRock10,028,5410 00For
State Street3,646,5320 010,715For
Fidelity3,158,4970 00For
Charles Schwab00 0768,350Withhold
Delaware/Macquarie00 0379,100Withhold
Aberdeen00 0266,041Withhold
First Trust00 0241,689Withhold
TIAA00 0210,638Withhold
Hartford182,8090 00For
Equitable119,4560 058,100Mixed
Jackson National130,9630 018,569Mixed
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle00 0129,106Withhold
Invesco100,6870 00For
Tema ETF Trust00 084,214Withhold
Prudential/PGIM00 078,129Withhold
Thrivent00 077,528Withhold
BNY Mellon74,7000 00For
Bridge Builder Trust22,0580 051,408Mixed
Principal00 072,189Withhold
ProShares00 066,038Withhold
Empower00 060,027Withhold
Lincoln Financial51,1000 07,101Mixed
Northern Trust49,4260 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Elect Director: Nicole Lambert

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 92,653,341WITHHELD: 11,634,189
Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: Election of Directors: Nicole Lambert

Arcus Biosciences, Inc.’s own tally for this item (“Elect Director: Nicole Lambert”): 92,653,341 for, 11,634,189 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 31,316,916 for, 2,074,339 withheld, 87 abstained.

FOR
FOR: 31,316,916ABSTAIN: 87WITHHOLD: 2,074,339
Largest asset managers voting on “Election of Directors: Nicole Lambert” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,445,2590 870For
BlackRock10,028,5410 00For
State Street3,652,6520 04,595For
Fidelity3,158,4970 00For
Charles Schwab768,3500 00For
Delaware/Macquarie00 0379,100Withhold
Aberdeen00 0266,041Withhold
First Trust00 0241,689Withhold
TIAA00 0210,638Withhold
Hartford182,8090 00For
Equitable119,4560 058,100Mixed
Jackson National00 0149,532Withhold
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle129,1060 00For
Invesco100,6870 00For
Tema ETF Trust84,2140 00For
Prudential/PGIM66,7230 011,406Mixed
Thrivent00 077,528Withhold
BNY Mellon00 074,700Withhold
Bridge Builder Trust22,0580 051,408Mixed
Principal00 072,189Withhold
ProShares00 066,038Withhold
Empower00 060,027Withhold
Lincoln Financial51,1000 07,101Mixed
Northern Trust49,4260 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 94,920,421AGAINST: 9,337,368

Prior year: 94.0% for (June 10, 2025 meeting) ▼ 2.9 pts

Details: description as filed, official tally, votes by 250 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Arcus Biosciences, Inc.’s own tally for this item (“3. The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 94,920,421 for, 9,337,368 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 73 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,433,18712,159 00For
BlackRock10,028,5410 00For
State Street3,655,4971,750 00For
Fidelity3,158,4970 00For
Charles Schwab768,3500 00For
Delaware/Macquarie379,1000 00For
Aberdeen0266,041 00Against
First Trust241,6890 00For
TIAA210,6380 00For
Hartford182,8090 00For
Equitable177,5560 00For
Jackson National130,96318,569 00Mixed
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle129,1060 00For
Invesco0100,687 00Against
Tema ETF Trust84,2140 00For
Prudential/PGIM078,129 00Against
Thrivent77,5280 00For
BNY Mellon74,7000 00For
Bridge Builder Trust73,4660 00For
Principal72,1890 00For
ProShares66,0380 00For
Empower60,0270 00For
Lincoln Financial51,1007,101 00Mixed
Northern Trust49,4260 00For

Fund voting reports, all 73 managers: 32,763,247 for, 618,715 against, 11,080 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 204 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE OFFICERS, AS DISCLOSE” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
GILEAD SCIENCES, INC.31,424,7600 00For
Wellington5,771,7050 00For
State Street5,336,83418,905 00For
BlackRock3,789,34723,495 00For
MONTANOVA CAPITAL, LLC3,605,2780 00For
Woodline Partners LP3,135,7090 00For
GEODE CAPITAL MANAGEMENT, LLC2,256,4710 00For
SAMLYN CAPITAL, LLC01,908,245 00Against
BNP Paribas Asset Management Holding S.A.01,654,754 00Against
Siren, L.L.C.1,395,0000 00For
Fidelity1,172,2180 00For
Trails Edge Capital Partners, LP1,134,9350 00For
Fisher Asset Management, LLC1,077,27635,078 00For
Logos Global Management LP01,100,000 00Against
Charles Schwab898,7620 00For
Candriam S.C.A.0790,613 00Against
Aberdeen0766,376 00Against
MARSHALL WACE, LLP727,3490 00For
Vanguard707,0360 00For
Northern Trust676,63711,006 00For
MELLON INVESTMENTS Corp494,5910 00For
Decheng Capital LLC477,8190 00For
DAFNA Capital Management LLC443,8290 00For
Sofinnova Investments, Inc.434,8680 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC423,8890 00For

Institutional-manager reports, all 204 managers: 69,957,259 for, 7,762,931 against, 45 abstained, 128 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 2 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 112,905,582AGAINST: 4,767,430

Prior year: 98.0% for (June 10, 2025 meeting) ▼ 2.1 pts

Details: description as filed, official tally, votes by 72 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF ARCUS BIOSCIENCES FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.

Arcus Biosciences, Inc.’s own tally for this item (“2. The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending Decemb”): 112,905,582 for, 4,767,430 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 32,474,930 for, 905,332 against, 11,080 abstained.

FOR
FOR: 32,474,930AGAINST: 905,332ABSTAIN: 11,080
Largest asset managers voting on “TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE INDEPEN” at Arcus Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard12,433,22012,126 00For
BlackRock10,028,5410 00For
State Street3,657,068179 00For
Fidelity3,158,4970 00For
Charles Schwab0768,350 00Against
Delaware/Macquarie379,1000 00For
Aberdeen266,0410 00For
First Trust241,6890 00For
TIAA210,6380 00For
Hartford182,8090 00For
Equitable177,5560 00For
Jackson National149,5320 00For
QUANTITATIVE MASTER SERIES LLC136,3190 00For
Columbia Threadneedle129,1060 00For
Invesco100,6870 00For
Tema ETF Trust84,2140 00For
Prudential/PGIM78,1290 00For
Thrivent77,5280 00For
BNY Mellon74,7000 00For
Bridge Builder Trust73,4660 00For
Principal72,1890 00For
ProShares66,0380 00For
Empower60,0270 00For
Lincoln Financial58,2010 00For
Northern Trust49,4260 00For

Showing the 25 largest of 72 asset managers. All 72 are in the interactive database (link above).

Largest Arcus Biosciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 125,773,162 shares outstanding at the time of that meeting.

Fund voting reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 9.90%
2BlackRock 7.97%
3State Street 2.91%
4Fidelity 2.51%
5Charles Schwab 0.61%
6Delaware/Macquarie 0.30%
7Aberdeen 0.21%
8First Trust 0.19%
9TIAA 0.17%
10Hartford 0.15%
Institutional-manager reports: top Arcus Biosciences, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE…”, 2025-2026
#Asset manager % of shares outstanding
1GILEAD SCIENCES, INC. 24.99%
2Wellington 4.59%
3State Street 4.26%
4BlackRock 3.03%
5MONTANOVA CAPITAL, LLC 2.87%
6Woodline Partners LP 2.49%
7GEODE CAPITAL MANAGEMENT, LLC 1.79%
8SAMLYN CAPITAL, LLC 1.52%
9BNP Paribas Asset Management Holding S.A. 1.32%
10Siren, L.L.C. 1.11%

Reported Arcus Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Arcus Biosciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Gilead Sciences, Inc.31,424,760 24.99%Schedule 13D, filed August 7, 2026
BlackRock, Inc.12,736,927 10.13%Schedule 13G, filed January 8, 2026
Vanguard Group7,962,874 6.33%Form 13F, quarter ended March 31, 2026
Wellington Management6,089,516 4.84%Form 13F, quarter ended March 31, 2026
State Street5,412,901 4.30%Form 13F, quarter ended March 31, 2026
Terry Rosen, Ph.D.2,592,608 2.06%Proxy statement (DEF 14A), table as of March 1, 2026
Geode Capital2,252,367 1.79%Form 13F, quarter ended March 31, 2026
Dimensional Fund Advisors1,426,223 1.13%Form 13F, quarter ended March 31, 2026
Citadel Advisors1,420,435 1.13%Form 13F, quarter ended March 31, 2026
Morgan Stanley1,210,754 0.96%Form 13F, quarter ended March 31, 2026

Percentages above are of 125,773,162 shares outstanding, as reported by Arcus Biosciences, Inc. on its Form 10-Q dated April 30, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Arcus Biosciences, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 250 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,990 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF ARCUS BIOSCIENCES' NAMED EXECUTIVE… — FOR was 91% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Arcus Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Arcus Biosciences, Inc.’s 10-Q dated April 30, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Arcus Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Arcus Biosciences (RCUS) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arcus-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.